Results 21 to 30 of about 4,014 (178)

Suspected fibrosing cholestatic hepatitis in an immunocompetent child with hepatitis C: Case report [PDF]

JPGN Rep
Abstract A 12‐year‐old boy presented to our center with elevated aminotransferases, jaundice, right upper quadrant tenderness, and hepatomegaly. Evaluation revealed a highly elevated blood hepatitis C virus (HCV) ribonucleic acid (RNA) level, and liver biopsy showed canalicular and intrahepatic cholestasis, feathery degeneration of hepatocytes, and ...
Bohon S, Gonzalez‐Peralta R, Fontana R, Cordle R, LeGallo R, DiPaola F.   +5 more
europepmc   +2 more sources

Biochemical study on the response to HCV therapy (Velpatasvir containing regimen), (vosevi) among adult patients’ non-responders to treatment in Fayoum Egypt [PDF]

Delta Journal of Science, 2023
Background: oral medications for the treatment of hepatitis C virus (HCV) infection, direct-acting antiviral agents (DAAs) are recommended. Worldwide, DAAs-based regimens have achieved excellent cure rates with a respectable profile of safety and a ...
Hasnaa Kamal, Nancy Atta, Naglaa Ismael, Heba Aldash, Ahmed Gomaa   +4 more
doaj   +1 more source

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

Frontiers in Pharmacology, 2020
BackgroundDirect-acting antivirals (DAAs) therapeutic regimens are highly effective against chronic hepatitis C virus (HCV) infection. However, HCV patients with genotype 3 (GT3) respond in a suboptimal way.
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor   +5 more
doaj   +1 more source

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3

Journal of University Medical & Dental College, 2020
BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virological Response (RVR) End of treatment response (ETR) and Sustained virological
Muhammad Sarfraz, Arshad Rabbani
doaj   +1 more source

Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

JGH Open, 2023
Background and Aim Sofosbuvir–velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes.
Chee‐Kiat Tan, Xue‐Shi Luo, Benjamin Shao‐Kiat Ong, Liang Lin, Kwong‐Hoe Ng   +4 more
doaj   +1 more source

Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection

, 2022
Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV infection. In the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for adults who previously received an HCV NS5A inhibitor.
Leszek Szenborn, Bandita Parhy, Anna Mania, Deirdre Kelly, Chia-Hsiang Hsueh, Sanjay Bansal, Vania Giacomet, Raffaele Iorio, Gabriella Nebbia, Kathryn Kersey, Jiang Shao, Mun Sang Yue, Alessandra Mangia, Guiseppe Indolfi, Malgorzata Pawlowska, Kersey K, Giacomet V, Shao J, Parhy B, Sang Yue M, Bansal S., Iorio R, Kelly D, Nebbia G, Szenborn L, Pawlowska M, Mangia A, Mania A, Indolfi G, Hsueh CH, Chia‐Hsiang Hsueh   +30 more
core   +2 more sources

Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report

, 2023
International audienceThis case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity.
Olivier Huillard, Audrey Thomas‐Schoemann, Benoit Blanchet, Préta, Laure‐hélène, Monribot, Anthia, Laurent Chouchana, Thomas-Schoemann, Audrey, Rui Batista, Chouchana, Laurent, Batista, Rui, Khoudour, Nihel, Pallet, Nicolas, Philippe Sogni, Blanchet, Benoit, Cabanes, Laure, Nicolas Pallet, François Goldwasser, Sogni, Philippe, Huillard, Olivier, Goldwasser, François, Anthia Monribot, Nihel Khoudour, Laure Cabanes, Laure‐Hélène Préta   +23 more
core   +1 more source

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials [PDF]

, 2017
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir ...
Eric Lawitz, Feld, JJ, Graham R. Foster, Bernard E. Willems, Norbert Bräu, Pearlman, B, Peter J. Ruane, Ira M. Jacobson, Robert H. Hyland, Tarik Asselah, Ronald G. Nahass, Dvory-Sobol, H, Jordan J. Feld, Shafran, SD, Thompson, AJ, Stamm, LM, Zhu, Y, Thomas Berg, Svarovskaia, E, Brainard, DM, Bräu, N, Berg, T, Asselah, T, Willems, BE, McHutchison, JG, Workowski, KA, Kosh Agarwal, Lawitz, E, Stephen D. Shafran, Brian Pearlman, Diana M. Brainard, G. Mani Subramanian, Stuart K. Roberts, Stedman, CAM, Dore, GJ, John G. McHutchison, Nahass, RG, Hadas Dvory-Sobol, Hyland, RH, Gane, EJ, Luisa M. Stamm, Catherine A.M. Stedman, Evguenia Svarovskaia, Jacobson, IM, Mitchell Davis, Agarwal, K, Bhandari, BR, Bal Raj Bhandari, Subramanian, GM, Borgia, SM, Roberts, SK, Alexander J. Thompson, Yanni Zhu, Ruane, PJ, Davis, M, Kimberly A. Workowski, Sergio M. Borgia, Gregory J. Dore, Dore, GJ ; https://orcid.org/, Foster, GR, Edward J. Gane   +60 more
core   +1 more source

Reimagining Hepatitis C Elimination: Time for Actions, Not Targets. [PDF]

J Int AIDS Soc
Journal of the International AIDS Society, Volume 29, Issue 8, August 2026.
Klein MB, Kronfli N, Young J.
europepmc   +2 more sources

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).

PLoS ONE, 2023
BackgroundHepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma. Globally, nearly 71 million people have chronic HCV infection, and approximately 399,000 dies annually.
Ashish Awasthi, Harshita Katiyar, Sumit Rungta, Amar Deep, Vinod Kumar, Shalimar, Ajay Kumar, Prachi Tiwari, Amit Goel   +8 more
doaj   +1 more source